中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
17期
98-99,100
,共3页
宫颈囊肿%壳聚糖宫颈抗菌膜%重组人干扰素%超声学%临床疗效
宮頸囊腫%殼聚糖宮頸抗菌膜%重組人榦擾素%超聲學%臨床療效
궁경낭종%각취당궁경항균막%중조인간우소%초성학%림상료효
cervical cyst%chitosan cervical antibacterial film%recombinant human interferon%ultrasonics%clinical curative effect
目的：对比研究壳聚糖宫颈抗菌膜、重组人干扰素局部用药对宫颈囊肿的临床疗效和超声学变化。方法选取2013年4月至7月收治的宫颈囊肿患者60例，按单发或多发、囊肿发病部位、是否伴宫颈肥胖平均分为壳聚糖宫颈抗菌膜组和重组人干扰素组，比较两组患者临床症状改善和总有效率以及超声学有效率，记录不良反应。结果治疗后两组患者分泌物、瘙痒评分均较治疗前显著下降（ P<0.01），灼烧和下腹疼痛评分下降（ P<0.05），壳聚糖宫颈抗菌膜组患者分泌物、灼烧评分降低更明显（ P<0.05）；壳聚糖宫颈抗菌膜组临床总有效率较重组人干扰素组略高，但差异无统计学意义（ P＞0.05）。壳聚糖宫颈抗菌膜组超声学总有效率比重组人干扰素组略高，但无统计学意义（ P＞0.05）。治疗过程中，两组均无明显不良反应。结论壳聚糖宫颈抗菌膜局部给药治疗宫颈囊肿，超声学总有效率有高于重组人干扰素，在改善临床症状方面优于重组人干扰素，且安全性高，值得临床推广。
目的：對比研究殼聚糖宮頸抗菌膜、重組人榦擾素跼部用藥對宮頸囊腫的臨床療效和超聲學變化。方法選取2013年4月至7月收治的宮頸囊腫患者60例，按單髮或多髮、囊腫髮病部位、是否伴宮頸肥胖平均分為殼聚糖宮頸抗菌膜組和重組人榦擾素組，比較兩組患者臨床癥狀改善和總有效率以及超聲學有效率，記錄不良反應。結果治療後兩組患者分泌物、瘙癢評分均較治療前顯著下降（ P<0.01），灼燒和下腹疼痛評分下降（ P<0.05），殼聚糖宮頸抗菌膜組患者分泌物、灼燒評分降低更明顯（ P<0.05）；殼聚糖宮頸抗菌膜組臨床總有效率較重組人榦擾素組略高，但差異無統計學意義（ P＞0.05）。殼聚糖宮頸抗菌膜組超聲學總有效率比重組人榦擾素組略高，但無統計學意義（ P＞0.05）。治療過程中，兩組均無明顯不良反應。結論殼聚糖宮頸抗菌膜跼部給藥治療宮頸囊腫，超聲學總有效率有高于重組人榦擾素，在改善臨床癥狀方麵優于重組人榦擾素，且安全性高，值得臨床推廣。
목적：대비연구각취당궁경항균막、중조인간우소국부용약대궁경낭종적림상료효화초성학변화。방법선취2013년4월지7월수치적궁경낭종환자60례，안단발혹다발、낭종발병부위、시부반궁경비반평균분위각취당궁경항균막조화중조인간우소조，비교량조환자림상증상개선화총유효솔이급초성학유효솔，기록불량반응。결과치료후량조환자분비물、소양평분균교치료전현저하강（ P<0.01），작소화하복동통평분하강（ P<0.05），각취당궁경항균막조환자분비물、작소평분강저경명현（ P<0.05）；각취당궁경항균막조림상총유효솔교중조인간우소조략고，단차이무통계학의의（ P＞0.05）。각취당궁경항균막조초성학총유효솔비중조인간우소조략고，단무통계학의의（ P＞0.05）。치료과정중，량조균무명현불량반응。결론각취당궁경항균막국부급약치료궁경낭종，초성학총유효솔유고우중조인간우소，재개선림상증상방면우우중조인간우소，차안전성고，치득림상추엄。
Objective To comparatively investigate the clinical effects and the ultrasonic change of chitosan cervical anti-bacterial membrane and recombinant human interferon by local application for treating cervical cyst in order to provide the reference for their clinical reasonable application. Methods 60 cases of cervical cyst in our hospital from April to July 2013 were selected and divided into the chitosan cervical anti-bacteria membrane group and the recombinant human interferon group according to single or multiple cyst, cyst site and cervical obesity. The improvement and total effective rates of clinical symptoms and the ultrasonic effective rates were compared between the two groups. The adverse reactions were recorded. Resuts The secretion and itching scores after treatment in the two groups were significantly decreased ( P<0. 01 ) , the ignition and lower abdominal pain scores were reduced ( P<0. 05 ) . Compared with the recombinant human interferon group, the decrease of the secretion and ignition scores in the chitosan cervical anti-bacteria membrane group was more significant, the difference between them had statistical significance ( P<0. 05 ) . The total effective rate in the chitosan cervical anti-bacteria membrane group was slightly higher than that in the recombinant human interferon group without statis-tical difference ( P>0. 05 ) . The ultrasonic effective rate in the chitosan cervical anti-bacteria membrane group was slightly higher than that in the recombinant human interferon group without statistical difference ( P>0. 05 ) . No obvious adverse reactions occurred during treatment process. Conclusion The chitosan cervical antibacterial film by local application has higher effective rate than the recombi-nant human interferon, is superior to the recombinant human interferon in improving the clinical symptoms, has high safety and deserves to be clinically promoted.
